Gilead Sciences GILD NASDAQ:GILD

NASDAQ Losers: Sodastream International (NASDAQ:SODA), Agios Pharmaceuticals (NASDAQ:AGIO), Penn National Gaming (NASDAQ:PENN), Susquehanna Bancshares Inc (NASDAQ:SUSQ)

SodaStream International Ltd. (NASDAQ:SODA) jumped again on Wednesday, this time by almost 11% on news that coffee giant, Starbucks Corporation (SBUX – Analyst Report) was in “advanced talks” to buy a 10% stake in the company. Sodastream International Ltd (NASDAQ:SODA) stock performance was -5.07% in last session and finished the day at $42.49. Traded volume was 3.07million shares in the last session and the average … Continue reading NASDAQ Losers: Sodastream International (NASDAQ:SODA), Agios Pharmaceuticals (NASDAQ:AGIO), Penn National Gaming (NASDAQ:PENN), Susquehanna Bancshares Inc (NASDAQ:SUSQ)

Watch List: Enservco Corp (NYSEMKT:ENSV), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Webster Financial Corporation (NYSE:WBS), SAP AG (NYSE:SAP)

Enservco Corp (NASDAQ:ENSV) was upgraded by equities researchers at TheStreet from a “hold” rating to a “buy” rating in a research report issued on Friday, AR Network reports. Enservco Corp (NYSEMKT:ENSV) stock performance was 3.72% in last session and finished the day at $2.23. Traded volume was 173.518million shares in the last session and the average volume of the stock remained 111.61K shares. The beta … Continue reading Watch List: Enservco Corp (NYSEMKT:ENSV), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Webster Financial Corporation (NYSE:WBS), SAP AG (NYSE:SAP)

Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -2.62% in last session and finished the day at $2.60. Traded volume was 16.17million shares in the last … Continue reading Investor’s Alert: Inovio Pharmaceuticals (NYSEMKT:INO), Synta Pharmaceuticals (NASDAQ:SNTA), Repligen Corporation (NASDAQ:RGEN), Agios Pharmaceuticals (NASDAQ:AGIO)

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago.  Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock performance was -5.92% in last session and finished the day at $62.35. Traded volume was 400.60K shares in the last session and the average volume of the … Continue reading Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)